VistaGen Therapeutics, Inc. (VTGN)
$0.21+0.00%Close
SELLCRISIS · day 11
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $9M
- Beta
- 0.39
- P/E (TTM)
- -0.12
- Short % float
- 10.70%
- Days to cover
- 1.0
- SI change
- +38.6%
- 1W
- -16.00%
- 1M
- -12.50%
- vs SPY 1W
- -15.86%
- vs SPY 1M
- -15.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 6
- GROWTH
- 54
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-91.6%
REV YoY-
ROE-45.8%
EPS YoY-
ROA-189.2%
GROSS85
OP-2784
NET-2703
[VALUATION]
P/E TTM-0.12
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.36
P/FCF-
EV/EBITDA0.10
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E3.20
ALTMAN Z-
CURR RATIO3.07
ND/EBITDA-
BETA0.39
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on VTGN?
- LOPJLB’s latest quantitative signal on VistaGen Therapeutics, Inc. (VTGN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is VTGN in?
- VistaGen Therapeutics, Inc. (VTGN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does VistaGen Therapeutics, Inc. (VTGN) do?
- VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults ex…